New Colon Cancer Screening Test Now Available In Alberta

Colon cancer screening

Sponsored content is written by Global News’ without any editorial influence by the sponsor. If you’d like to learn more… CALGARY- People over 50 with an average risk of developing colon cancer can now access a new screening test in Alberta. The fecal immunochemical test has been available since November. Also known as FIT, the test requires a small stool sample that can be collected by patients in their own homes. Story continues below The test uses antibodies that bind to human blood protein that may be found in the stool, explains Dr. Steven Heitman, medical director of the Forzani & MacPhail Colon Cancer Screening Centre. It is able to detect blood specific to bleeding in the colon which can indicate cancer or a [pre-cancerous] polyp. The FIT test is not intended to replace a colonoscopy, which remains the gold standard for colon cancer screening. Instead, FIT will be used to triage patients considered average risk. The test is really directed towards those that are 50 to 74 years of age who are asymptomatic and lack that family history or personal history of colon cancer. Until now, those average risk patients were put to the back of the line for colonoscopy, waiting up to two years for their turn. Average risk patients who show no sign of cancer after their first colonoscopy often wait up to 10 years for a second screening. New Alberta guidelines recommend patients are screened with the FIT test annually. Sonja Chycoski fell into the average risk category when she began experiencing rectal bleeding in 2011. I went to the doctor and because I had had a colonoscopy five or six years before, they said its got to be hemorrhoids, she recalls. Chycoski waited over a year for another colonoscopy. She was eventually diagnosed with stage 4 colon cancer.

try what he says

Colorectal Cancer Market Analysis and 2019 Forecasts in New Research Report at

Scope A brief introduction to colorectal cancer, including the diseases pathogenesis, etiology, diagnosis and treatment algorithms. In-depth analysis of the three mAbs marketed for colorectal cancer, including analysis of their safety, efficacy, treatment patterns and strengths/weaknesses. Including a heat map comparing the drugs in terms of safety and efficacy. A comprehensive review of the pipeline for colorectal cancer therapies, including individual analysis of a number of late-stage pipeline drugs that are likely to enter the market during the forecast period. The pipeline is analyzed on the basis of phase distribution, molecule types, program types, mechanisms of action and molecular targets. Additional in-depth analysis of pipeline drug clinical trials by phase, trial size, trial duration and program failure rate for each molecule type, in addition to an in-depth analysis of clinical trial primary endpoints. Multi-scenario forecast data of the market to 2019, taking into account how the market may be affected by the introduction of new drugs, the expiry of key patents on current drugs and the changes in disease epidemiology across the key developed markets. Discussion of the drivers and barriers for market growth. In-depth analysis of all licensing and co-development deals that have occurred in the colorectal cancer market since 2006. Reasons to Buy Understand the role of mAbs in the treatment of colorectal cancer and their relation to chemotherapies and targeted small molecule therapies. Understand the vast scope of the pipeline, including which molecule types and mechanisms of action are prominent. Observe the trends in clinical trial duration and size amongst clinical phases and molecule types.

secret info

Albert Cilia-Vincenti, Scientific delegate to European Medicines Agency, Attard Colon cancer screening The story on recovering from colon cancer (Diving back into a life without cancer, The Sunday Times of Malta, December 8) had some useful points, in particular the list of possible symptoms of the condition, but otherwise lacked other useful information. This is one of the most common cancers in both men and women, particularly in the Western industrialised countries. Except where there are strong hereditary defects, colon cancer appears to be particularly related to excessive meat consumption (especially processed meat like salami, ham and bacon), insufficient vegetables and fruits in the diet, and possibly obesity, lack of exercise and excessive alcohol consumption. Taking a small daily dose of aspirin reduces colon cancer risk by around 50 per cent, and fish oil may have a similar effect. There is also interest in the possible colon cancer risk reduction of probiotics capsules or liquids containing good bacteria which can replace bad ones in the colon. Screening for colon cancer aims to detect it at an early stage where surgery alone can be curative. There are two main colonic screening methods, the faecal occult blood (FOB) test, and colonoscopy. Colonoscopy is superior because it can detect and remove small pre-cancerous nodules (thus preventing progression to cancer), but is very expensive compared to the FOB test, which the individual performs at home and posts to the laboratory. The FOB test is inferior to colonoscopy in that it tends to detect established cancer rather than pre-cancerous lesions. However, the FOB test has the potential of detecting established cancer at an earlier curable stage. The UK NHS is about to publish the results of its pilot FOB population screening study, which will show a 10 per cent reduction in colonic cancer mortality with only up to 50 per cent response rate to invitations to do the test (only 30 per cent response in some ethnic groups). The UK NHS has chosen the FOB test as its colonic screening tool. It reckons that colonoscopy for population screening is too expensive and that NHS endoscopy units would not be able to cope with the demand. Cross-country charity challenge Will lawyers speak out? Advert Comments are submitted under the express understanding and condition that the editor may, and is authorised to, disclose any/all of the above personal information to any person or entity requesting the information for the purposes of legal action on grounds that such person or entity is aggrieved by any comment so submitted. At this time your comment will not be displayed immediately upon posting.

visit site


Leave a Reply

Fill in your details below or click an icon to log in: Logo

You are commenting using your account. Log Out /  Change )

Google+ photo

You are commenting using your Google+ account. Log Out /  Change )

Twitter picture

You are commenting using your Twitter account. Log Out /  Change )

Facebook photo

You are commenting using your Facebook account. Log Out /  Change )


Connecting to %s